Please use this identifier to cite or link to this item:
|Title:||Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial||Authors:||Back, Michael ;Khasraw, M.;Lee, A.;McCowatt, S.;Kerestes, Z.;Buyse, M.;Kichenadasse, G.;Ackland, S.;Wheeler, H.||Affliation:||Central Coast Local Health District
Northern Sydney Central Coast Health
|Issue Date:||May-2016||Source:||Volume 128, Issue 1, pp. 163 - 171||Journal title:||Journal of Neuro-oncology||Department:||Radiation Oncology||Abstract:||Newly diagnosed glioblastoma multiforme with unmethylated MGMT promoter has a poor prognosis, with a median survival of 12 months. This phase II study investigated the efficacy and safety of combining the selective integrin inhibitor cilengitide with a combination of metronomic temozolomide and procarbazine for these patients. Eligible patients (newly diagnosed, histologically confirmed supratentorial glioblastoma with unmethylated MGMT promoter) were entered into this multicentre study. Cilengitide (2000 mg IV twice weekly) was commenced 1 week prior to radiotherapy combined with daily temozolomide (60 mg/m(2)) and procarbazine (50 or 100 mg) and, after 4 weeks' break, followed by six adjuvant cycles of temozolomide (50-60 mg/m(2)) and procarbazine (50 or 100 mg) on days 1-20, every 28 days. Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity. The primary endpoint for efficacy was a 12-month overall survival rate of 65 %. Twenty-nine patients completed study treatment. Sixteen patients survived for 12 months or more, an overall survival rate of 55 %. The median overall survival was 14.5 months (95 % CI 11.1-19.6) and the median progression-free survival was 7.4 months (95 % CI 6.1-8). Cilengitide combined with metronomic temozolomide and procarbazine in MGMT-promoter unmethylated glioblastoma did not improve survival compared with historical data and does not warrant further investigation.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1246||DOI:||10.1007/s11060-016-2094-0||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/26935578||ISSN:||0167-594x||Publicaton type:||Journal Article||Keywords:||Cancer
|Appears in Collections:||Oncology / Cancer|
Show full item record
checked on Sep 29, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.